Thomas Hallam
Net worth: 12 $ as of 2024-03-30
Profile
Thomas M.
Hallam served as the Chief Executive Officer & Director at Leading Biosciences, Inc. from 2017 to 2022.
He also served as the Chief Executive Officer & Director at Palisade Bio, Inc. from 2021 to 2022.
Prior to that, he was the Director-Therapeutic Programs at Mesoblast Ltd.
from 2012 to 2014.
He also worked as the Medical Director at Saatchi & Saatchi North America LLC.
Additionally, he served as the Director-Therapeutic Programs at Mesoblast, Inc. Dr. Hallam holds an MBA degree from the University of Southern California, a doctorate degree from the University of California, Davis, and an undergraduate degree from the University of Illinois.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
PALISADE BIO, INC.
0.00% | 2024-03-14 | 31 ( 0.00% ) | 12 $ | 2024-03-30 |
Former positions of Thomas Hallam
| Companies | Position | End |
|---|---|---|
Leading Biosciences, Inc.
 Leading Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Leading Biosciences, Inc. provides healthcare services. It offers therapy for severe sepsis, septic shock, and multi-organ failure. The company was founded by John Rodenrys and is headquartered in Carlsbad, CA. | Chief Executive Officer | 2022-10-10 |
| PALISADE BIO, INC. | Chief Executive Officer | 2022-10-10 |
| MESOBLAST LIMITED | Corporate Officer/Principal | 2013-12-31 |
Saatchi & Saatchi North America LLC
 Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Chief Tech/Sci/R&D Officer | - |
Mesoblast, Inc.
 Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Thomas Hallam
| University of Southern California | Masters Business Admin |
| University of California, Davis | Doctorate Degree |
| University of Illinois | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| MESOBLAST LIMITED | Health Technology |
| PALISADE BIO, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Mesoblast, Inc.
Mesoblast, Inc. Pharmaceuticals: MajorHealth Technology Mesoblast, Inc. manufactures and distributes biopharmaceutical products. It develops cellular medicines for under-served therapeutic areas including cardiac diseases, spine orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. The company was founded by Michael Schuster and Silviu Itescu in 2004 and is headquartered in New York, NY. | Health Technology |
Saatchi & Saatchi North America LLC
Saatchi & Saatchi North America LLC Advertising/Marketing ServicesCommercial Services Saatchi & Saatchi North America, Inc. provides advertising services. It offers creative advertising services and plans marketing campaigns for advertisers and global companies. The company was founded in 1970 and is headquartered in New York, NY. | Commercial Services |
Leading Biosciences, Inc.
Leading Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Leading Biosciences, Inc. provides healthcare services. It offers therapy for severe sepsis, septic shock, and multi-organ failure. The company was founded by John Rodenrys and is headquartered in Carlsbad, CA. | Commercial Services |
- Stock Market
- Insiders
- Thomas Hallam
